What to Know About Ozempic and Gastroparesis: Patterns in Medical Literature

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Mass Production Liability

If you're experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering about gastroparesis. Decades of pharmacovigilance research have established a framework for identifying and documenting medication-related adverse effects. This page summarizes the case patterns reported in medical literature regarding Ozempic and gastroparesis, helping you understand the evidence.

Pharmacological Link Between Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, presents clinically with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. The overlap between Ozempic's intended effects on gastric motility and the pathophysiology of gastroparesis has raised concerns about a potential causal link. Clinical trial data from the Ozempic prescribing information document a significantly higher incidence of gastrointestinal adverse reactions in treated patients compared to placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea reports occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in at least 5% of Ozempic-treated patients included nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal symptoms, which are consistent with the clinical presentation of gastroparesis.

Mechanistic Pathway and Warning Adequacy

The mechanistic pathway linking Ozempic to gastroparesis involves its action as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract and central nervous system, and their activation slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone. While this effect is therapeutic for glycemic control, it can become pathological in susceptible individuals, leading to persistent delayed gastric emptying and symptomatic gastroparesis. The prescribing information does not explicitly list gastroparesis as a warning or adverse reaction, but it does include warnings for serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific gastroparesis warning raises questions about the adequacy of warnings provided to patients and healthcare providers regarding this potential risk. From a risk perspective, patients who develop gastroparesis after using Ozempic may face significant health consequences, including malnutrition, dehydration, and reduced quality of life. The timeline between exposure and documented harm is critical for legal and settlement considerations. Gastrointestinal adverse reactions often occur during dose escalation, as noted in clinical trials, but symptoms may persist or worsen with continued use.

Statute of Limitations and Settlement Considerations in Michigan

For patients in Michigan, the statute of limitations for product liability claims, including those related to inadequate warnings, is generally three years from the date of injury or discovery of the injury. However, this timeline can vary based on specific circumstances, such as when the patient reasonably should have connected the harm to Ozempic use. Settlement-related considerations for affected patients include the need to document the temporal relationship between Ozempic use and the onset of gastroparesis symptoms, as well as any medical records confirming the diagnosis. The adequacy of warnings is a central issue: if the prescribing information did not sufficiently alert patients and physicians to the risk of gastroparesis, manufacturers may be held liable for failure to warn. Evidence from clinical trials shows that gastrointestinal adverse reactions are common and dose-dependent, but the label does not specifically address gastroparesis as a distinct adverse event. This gap may support claims that the risk was not adequately communicated. In summary, the evidence demonstrates a plausible link between Ozempic use and gastroparesis through its pharmacological effects on gastric emptying. Clinical trial data confirm a high incidence of gastrointestinal symptoms that align with gastroparesis presentation. The adequacy of warnings is questionable given the absence of a specific gastroparesis warning in the label. Patients in Michigan should be aware of the statute of limitations and seek legal counsel to evaluate their individual circumstances, including the timing of exposure and diagnosis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Michigan?

In Michigan, the statute of limitations for product liability claims, including failure to warn, is generally three years from the date of injury or discovery of the injury. However, this can vary based on when the patient reasonably should have connected the harm to Ozempic use. It is crucial to consult with an attorney to determine the applicable deadline for your specific case.

Does Ozempic cause gastroparesis?

Clinical trial data show that Ozempic significantly increases gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain, which are consistent with gastroparesis symptoms. The drug's mechanism of slowing gastric emptying can lead to pathological delayed emptying in susceptible individuals, suggesting a plausible link. However, the prescribing information does not explicitly list gastroparesis as a warning.

What evidence supports a link between Ozempic and gastroparesis?

Evidence includes clinical trial data from the prescribing information showing dose-dependent increases in gastrointestinal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Mechanistically, Ozempic activates GLP-1 receptors, which slow gastric emptying. This overlap with gastroparesis pathophysiology supports a causal relationship.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.